combination therapy with glp-1 receptor agonist and sglt2 inhibitor Combining Agonists Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Assessing the proportion of patients

Many patients with HFpEF have underlying coronary artery disease

A fresh analysis of the clinical and financial implications of comprehensive coverage in Medicare of GLP-1s for all current FDA indications (type 2 diabetes, obesity, heart disease and metabolic-associated steatohepatitis) offers some hope for long-term cost savings

A 12-week medication course addresses none of these underlying drivers in a permanent way

GLP-1 RA, mainly liraglutide, might represent interesting molecules to tackle the weight excess that is associated with metabolic abnormalities, hyperandrogenism, infertility, and menstrual alterations in PCOS women

doi: 10.1172/JCI75276

Careful monitoring for such adverse effects is crucial, and these medications should be integrated with lifestyle interventions for holistic obesity treatment